[go: up one dir, main page]

BR9803883A - Derivado de amida. - Google Patents

Derivado de amida.

Info

Publication number
BR9803883A
BR9803883A BR9803883-4A BR9803883A BR9803883A BR 9803883 A BR9803883 A BR 9803883A BR 9803883 A BR9803883 A BR 9803883A BR 9803883 A BR9803883 A BR 9803883A
Authority
BR
Brazil
Prior art keywords
group
substituted
formula
activated
release
Prior art date
Application number
BR9803883-4A
Other languages
English (en)
Inventor
Hirokazu Kubota
Yasuhiro Yonetoku
Keizou Sugasawa
Masashi Funatsu
Souichirou Kawazoe
Akira Toyoshima
Yoshinori Okamoto
Jun Ishikawa
Makoto Takeuchi
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of BR9803883A publication Critical patent/BR9803883A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADO DE AMIDA". A presente invenção refere-se a um medicamento, particularmente a um derivado de amida pela seguinte fórmula geral (I') tendo uma ação de inibir o canal de Ca^ 2+^ ativado de liberação de Ca^ 2+^, e uma composição farmacêutica contendo o mesmo como um ingrediente ativo, particularmente um inibidor de canal de Ca^ 2+^ ativado de liberação de Ca^ 2+^. (os símbolos na fórmula tendo os seguintes significados: D representa um grupo pirazolila que pode ter de 1 a 3 grupos alquila inferiores insubstituidos ou substituídos por halogênio como substituintes, B representa um grupo fenileno ou tiofenediila, X representa um grupo de fórmula -NH-CO- ou -CO-NH-, e A representa um grupo fenila que pode ser substituído com um ou mais átomos de halogênio, ou um grupo heteroarila monocíclico de cinco ou seis membros que pode ser substituído por um ou mais grupos de alquila inferior.
BR9803883-4A 1997-10-13 1998-10-06 Derivado de amida. BR9803883A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP27909397 1997-10-13

Publications (1)

Publication Number Publication Date
BR9803883A true BR9803883A (pt) 2000-05-16

Family

ID=17606326

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9803883-4A BR9803883A (pt) 1997-10-13 1998-10-06 Derivado de amida.

Country Status (18)

Country Link
US (4) US6348480B1 (pt)
EP (1) EP1024138B1 (pt)
KR (1) KR100589868B1 (pt)
CN (1) CN1107671C (pt)
AR (1) AR016957A1 (pt)
AT (1) ATE360618T1 (pt)
AU (2) AU751139B2 (pt)
BR (1) BR9803883A (pt)
CA (1) CA2304979A1 (pt)
DE (1) DE69837675T2 (pt)
ES (1) ES2285784T3 (pt)
HU (1) HUP9802310A1 (pt)
NO (1) NO317417B1 (pt)
PL (1) PL192411B1 (pt)
PT (1) PT1024138E (pt)
RU (1) RU2185381C2 (pt)
TW (1) TW495498B (pt)
WO (1) WO1999019303A1 (pt)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751139B2 (en) * 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
WO1999051580A1 (en) * 1998-04-08 1999-10-14 Abbott Laboratories Pyrazole inhibitors of cytokine production
US6506747B1 (en) * 1998-06-05 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
EP1100495A4 (en) * 1998-07-28 2002-09-25 Smithkline Beecham Corp PROPENAMIDES AS CCR5 MODULATORS
AU753360B2 (en) * 1998-07-31 2002-10-17 Nippon Soda Co., Ltd. Phenylazole compounds, process for producing the same and drugs for hyperlipemia
JP2001031509A (ja) * 1999-07-15 2001-02-06 Nippon Bayer Agrochem Co Ltd チエニル−ピラゾール類の有害生物防除剤としての利用
CA2397493A1 (en) * 2000-01-27 2001-08-02 Cytovia, Inc. Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6451820B1 (en) 2000-03-23 2002-09-17 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenly)triazoles and their use as anti-inflammatory agents
US6353007B1 (en) * 2000-07-13 2002-03-05 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)indoles and their use as anti-inflammatory agents
EP1186661A1 (en) * 2000-09-05 2002-03-13 Warner-Lambert Company Identification of the major capacitative calcium channel in antigen presenting cells and uses thereof
EP1184457A1 (en) * 2000-09-05 2002-03-06 Warner-Lambert Company Identification of a capacitative calcium channel in antigen presenting cells and uses thereof
CN1289072C (zh) * 2000-12-22 2006-12-13 石原产业株式会社 苯胺衍生物或其盐以及含有它们的细胞因子产生抑制剂
WO2002098363A2 (en) * 2001-06-06 2002-12-12 Agouron Pharmaceuticals, Inc. NON-PEPTIDE GnRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USES, AND PROCESSES FOR PREPARING THEM
CA2449486A1 (en) 2001-06-29 2003-01-09 Boehringer Ingelheim Pharmaceuticals Inc. Methods of using soluble epoxide hydrolase inhibitors
GB0209715D0 (en) * 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
EP1548015A1 (en) * 2002-08-27 2005-06-29 Yamanouchi Pharmaceutical Co. Ltd. Novel crystals
JP2006506366A (ja) * 2002-10-18 2006-02-23 ファイザー・プロダクツ・インク カンナビノイド受容体リガンドおよびその使用方法
US7790724B2 (en) * 2003-04-25 2010-09-07 Janssen Pharmaceutica N.V. c-fms kinase inhibitors
CA2533598C (en) * 2003-07-23 2012-09-11 Synta Pharmaceuticals, Corp. Method for modulating calcium ion-release-activated calcium ion channels
US8247576B2 (en) 2003-12-23 2012-08-21 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
ATE432273T1 (de) * 2004-03-09 2009-06-15 Boehringer Ingelheim Pharma 3-ä4-heterocyclyl-1,2,3-triazol-1-ylü-n- arylbenzamide als inhibitoren der cytokinenproduktion für die behandlung von chronischen entzündlichen erkrankungen
AU2005226741A1 (en) * 2004-03-25 2005-10-06 Synta Pharmaceuticals Corp. Acrylonitrile derivatives for inflammation and immune-related uses
TW200633990A (en) * 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
WO2006115140A1 (ja) * 2005-04-22 2006-11-02 Astellas Pharma Inc. 腸疾患の予防若しくは治療剤
GB2427406A (en) * 2005-06-21 2006-12-27 Astex Technology Ltd Silicon-containing PKB/PKA kinase inhibitors
WO2006136821A1 (en) 2005-06-22 2006-12-28 Astex Therapeutics Limited Pharmaceutical compounds
JP5345842B2 (ja) 2005-06-23 2013-11-20 アステックス・セラピューティクス・リミテッド プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ
CA2640091A1 (en) * 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Vinyl-phenyl derivatives for inflammation and immune-related uses
EP2465850B1 (en) * 2006-02-28 2016-11-23 Dart Neuroscience (Cayman) Ltd Therapeutic compounds
AU2013200480B2 (en) * 2006-02-28 2016-06-09 Dart Neuroscience (Cayman) Ltd. Therapeutic compounds
AU2007221021B2 (en) 2006-02-28 2013-01-17 Dart Neuroscience (Cayman) Ltd Therapeutic piperazines as PDE4 inhibitors
US7803799B2 (en) * 2006-07-07 2010-09-28 National Health Research Institutes Selenophene compounds
JPWO2008016131A1 (ja) * 2006-08-04 2009-12-24 武田薬品工業株式会社 縮合複素環化合物
RU2009110254A (ru) * 2006-08-24 2010-09-27 Новартис АГ (CH) Производные 2-(пиразин-2-ил)тиазола и 2-(1н-пиразол-3-ил)тиразола и связанные с ним соединения в качестве ингибиторов стеароил-соа десатуразы для лечения метаболических, сердечно-сосудистых и других нарушений
JP5336375B2 (ja) 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
TWI339205B (en) * 2006-10-02 2011-03-21 Nat Health Research Institutes Pyrazole compounds and pharmaceutical composition
TWI408136B (zh) * 2006-10-02 2013-09-11 Nat Health Research Institutes 噻吩化合物及其醫藥組成物
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
NZ580195A (en) * 2007-03-05 2012-03-30 Univ Queensland Targeting crac for breast cancer therapy and/or diagnosis
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
AU2008293542B9 (en) 2007-08-27 2014-08-07 Dart Neuroscience (Cayman) Ltd. Therapeutic isoxazole compounds
GB0801888D0 (en) * 2008-02-01 2008-03-12 Isis Innovation Treatment of mast cell related disorders
DE102008014523A1 (de) * 2008-03-15 2009-09-17 Robert Bosch Gmbh Heizgerät
EP2565191B1 (en) * 2008-05-14 2014-10-08 Astellas Pharma Inc. 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy
JP2010030970A (ja) * 2008-07-31 2010-02-12 Bayer Cropscience Ag 殺虫性ベンゼンジカルボキサミド誘導体
TWI434686B (zh) * 2008-11-03 2014-04-21 Nat Health Research Institutes 咪唑－４－酮及咪唑－４－硫酮化合物
CA2750565C (en) * 2009-01-30 2015-10-20 Glaxosmithkline Llc Crystalline n-{(1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
AR076373A1 (es) * 2009-04-24 2011-06-08 Glaxo Group Ltd N-pirazolil carboxamidas como inhibidores de canales de calcio
JP2012524754A (ja) 2009-04-24 2012-10-18 グラクソ グループ リミテッド Ｃｒａｃチャネル阻害剤としてのピラゾールおよびトリアゾ−ルカルボキサミド
WO2010126002A1 (ja) * 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
EP2440553B1 (en) * 2009-06-12 2017-08-23 Merck Sharp & Dohme Corp. Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
US8993612B2 (en) * 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
US8377970B2 (en) * 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
DK2563776T3 (en) 2010-04-27 2016-09-19 Calcimedica Inc Relations that modulate intracellular calcium
JP2013525448A (ja) 2010-04-27 2013-06-20 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
WO2012027710A2 (en) * 2010-08-27 2012-03-01 Calcimedica Inc. Compounds that modulate intracellular calcium
WO2012052458A1 (en) 2010-10-21 2012-04-26 Glaxo Group Limited Pyrazole compounds acting against allergic, immune and inflammatory conditions
US9149462B2 (en) 2010-10-21 2015-10-06 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
CN103702665B (zh) 2011-05-03 2016-08-17 幸讬制药公司 用于炎症和免疫相关用途的化合物
WO2012170931A2 (en) 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013059677A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013059666A1 (en) * 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2844656A1 (en) 2012-05-02 2015-03-11 Lupin Limited Substituted pyrazole compounds as crac modulators
WO2014059333A1 (en) * 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
HK1216300A1 (zh) 2013-01-10 2016-11-04 Grünenthal GmbH 作为crac通道抑制剂的基於吡唑基的甲醯胺i
KR20150103752A (ko) 2013-01-10 2015-09-11 그뤼넨탈 게엠베하 Crac 채널 억제제로서의 피라졸릴계 카복스아미드 ⅱ
CA2919828C (en) 2013-07-30 2022-07-19 Phaserx, Inc. Block copolymers and their conjugates or complexes with oligonucleotides
WO2015090599A1 (en) * 2013-12-19 2015-06-25 Grünenthal GmbH Fluoromethyl-substituted pyrrole carboxamides iv
MX2016007955A (es) * 2013-12-19 2016-09-09 Gruenenthal Gmbh Pirrol carboxamidas iii fluorometil-sustituidas.
CN104926801B (zh) * 2014-03-22 2019-06-04 浙江大学 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用
WO2015197187A1 (en) 2014-06-24 2015-12-30 Grünenthal GmbH Pyrazolyl-based carboxamides v
WO2016118697A1 (en) 2015-01-21 2016-07-28 Phaserx, Inc. Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
TWI835179B (zh) 2015-02-27 2024-03-11 美商鈣系醫藥公司 胰腺炎治療
DK3331525T3 (da) 2015-08-07 2020-12-14 Calcimedica Inc Anvendelse af CRAC-kanal-inhibitorer til behandling af slagtilfælde og traumatisk hjerneskade
CN105503832B (zh) * 2015-12-18 2018-03-27 浙江大学 取代吡唑环类衍生物及其用途
WO2018126084A1 (en) 2016-12-30 2018-07-05 Phaserx, Inc. Branched peg molecules and related compositions and methods
CA3112907A1 (en) 2018-09-14 2020-03-19 Rhizen Pharmaceuticals Ag Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof
CN111187204B (zh) * 2020-01-13 2022-11-08 海利尔药业集团股份有限公司 一种啶虫脒共晶及其制备方法、用途
EP4110775A1 (en) * 2020-02-28 2023-01-04 Remix Therapeutics Inc. Thiophenyl derivatives useful for modulating nucleic acid splicing
EP4243813A4 (en) 2020-11-13 2024-07-17 Calcimedica, Inc. IMPROVED SYNTHESIS OF CRAC CHANNEL INHIBITORS
WO2024126777A1 (en) * 2022-12-16 2024-06-20 Astrazeneca Ab Heteroaromatic compounds

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3401911A1 (de) * 1984-01-20 1985-08-01 A. Nattermann & Cie GmbH, 5000 Köln Substituierte 4,5-dihydro-6-vinyl-3(2h)-pyridazinone und 6-vinyl-3(2h)-pyridazinone sowie verfahren zu ihrer herstellung
GB8409986D0 (en) * 1984-04-17 1984-05-31 Beecham Group Plc Beta-lactam antibacterial agents
PT80533B (en) * 1984-05-29 1987-04-06 Pfizer Process for preparing quinolone inotropic agents
JPS6455557A (en) * 1987-08-26 1989-03-02 Fuji Photo Film Co Ltd Silver halide color photographic sensitive material
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
JPH0419721Y2 (pt) 1987-09-29 1992-05-06
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
JP2867450B2 (ja) 1989-08-17 1999-03-08 吉富製薬株式会社 アルキレンビスアミド化合物
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
FR2659655B1 (fr) 1990-03-19 1992-07-24 Union Pharma Scient Appl Nouveaux derives d'oxypyrazole antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant.
DE4126994A1 (de) * 1991-08-16 1993-02-18 Basf Ag (alpha)-arylacrylsaeurederivate, ihre herstellung und verwendung zur bekaempfung von schaedlingen und pilzen
JP3141261B2 (ja) 1992-10-22 2001-03-05 松下電工株式会社 警報表示器
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
JPH07225401A (ja) * 1994-02-14 1995-08-22 Fuji Photo Film Co Ltd 非線形光学材料
WO1995032963A1 (en) * 1994-06-01 1995-12-07 Yoshitomi Pharmaceutical Industries, Ltd. Thienylazole compound and thienotriazolodiazepine compound
GB9414139D0 (en) * 1994-07-13 1994-08-31 Smithkline Beecham Plc Novel compounds
WO1996010559A1 (en) * 1994-10-04 1996-04-11 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
PL184490B1 (pl) * 1995-02-02 2002-11-29 Smithkline Beecham Plc Nowe pochodne indolu jako antagonista receptora T
WO1996031517A1 (en) * 1995-04-04 1996-10-10 E.I. Du Pont De Nemours And Company Herbicidal heteroaryl-substituted anilides
BR9606546A (pt) 1995-08-02 1998-07-14 Uriach & Cia Sa J Novas carboxamidas com atividade fungicida
JPH1072434A (ja) * 1996-04-08 1998-03-17 Nissan Chem Ind Ltd ２，４−置換アニリン誘導体
EP0987250A4 (en) 1997-02-20 2000-12-06 Shionogi & Co INDOLDICARBONIC ACID DERIVATIVES
AU6320998A (en) * 1997-02-21 1998-09-09 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
DE19708928A1 (de) * 1997-03-05 1998-09-10 Bayer Ag Substituierte aromatische Aminoverbindungen
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
AU751139B2 (en) * 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
WO1999051580A1 (en) * 1998-04-08 1999-10-14 Abbott Laboratories Pyrazole inhibitors of cytokine production
US6506747B1 (en) * 1998-06-05 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
US6140509A (en) * 1998-06-26 2000-10-31 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US20010044445A1 (en) * 1999-04-08 2001-11-22 Bamaung Nwe Y. Azole inhibitors of cytokine production

Also Published As

Publication number Publication date
EP1024138B1 (en) 2007-04-25
US7247635B2 (en) 2007-07-24
HU9802310D0 (en) 1998-12-28
AU751139B2 (en) 2002-08-08
PL329150A1 (en) 1999-04-26
WO1999019303A1 (en) 1999-04-22
US20050234055A1 (en) 2005-10-20
NO20001907D0 (no) 2000-04-12
KR19990037018A (ko) 1999-05-25
US6958339B2 (en) 2005-10-25
DE69837675T2 (de) 2008-01-10
EP1024138A1 (en) 2000-08-02
US20060264430A1 (en) 2006-11-23
CA2304979A1 (en) 1999-04-22
ES2285784T3 (es) 2007-11-16
NO20001907L (no) 2000-06-09
CN1107671C (zh) 2003-05-07
US6348480B1 (en) 2002-02-19
RU2185381C2 (ru) 2002-07-20
TW495498B (en) 2002-07-21
PT1024138E (pt) 2007-08-01
KR100589868B1 (ko) 2006-10-24
US20010011090A1 (en) 2001-08-02
AU9459398A (en) 1999-05-03
EP1024138A4 (en) 2002-02-06
ATE360618T1 (de) 2007-05-15
AR016957A1 (es) 2001-08-01
DE69837675D1 (en) 2007-06-06
PL192411B1 (pl) 2006-10-31
US7285554B2 (en) 2007-10-23
AU8713998A (en) 1999-04-29
CN1218046A (zh) 1999-06-02
NO317417B1 (no) 2004-10-25
HUP9802310A1 (hu) 2000-03-28

Similar Documents

Publication Publication Date Title
BR9803883A (pt) Derivado de amida.
NO933482D0 (no) N-sulfonyl-2-oksoindol-derivater som har affinitet for vasopressin- og/eller ocytocin-reseptorer
BR0307575A (pt) Derivados de sulfonila como inibidores de histona desacetilase
BR0307599A (pt) Derivados de sulfonilamino como inibidores de histona deacetilase
PT1058683E (pt) Inibidores da farnesil-transferase com uma estrutura de piperidina e seu processo de preparacao
BR0307606A (pt) Derivados de piperazinila, piperidinila e morfolinila como inibidores de histona desacetilase
TR199800825T2 (xx) Farnesil protein transferini inhibe eden (imidazol-5-il) metil-2-kinolinon t�revleri.
DK0691953T3 (da) 1-amidinophenyl-pyrrolidoner/piperidinoner som blodpladeaggreerende inhibiorer
BRPI0410630A (pt) antagonista de nk1
BR9913592A (pt) Compostos, processo de preparação dos compostos, e, composições farmacêuticas
BR0307607A (pt) Derivados de carbonilamino como inibidores de histona desacetilase
DK1140918T3 (da) Thrombininhibitorer
DE60118225D1 (de) Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
ATE281149T1 (de) Kosmetische zusammensetzungen
TR200101961T2 (tr) 1,2-halkalı kinolin türevleri
BR0010520A (pt) Novos compostos farmaceuticamente ativos
PA8548001A1 (es) Derivados aromaticos de acidos dicarboxilicos
EA199900937A1 (ru) Фармацевтические композиции, содержащие вориконазол
BR9811521A (pt) Composição para tratar ou impedir a glomerulopatia
NO963370D0 (no) Nye mercaptoacetylamido-1,3,4,5-tetrahydro-benzo[cÅazepin-3-on-disulfidderivater som er anvendbare som inhibitorer av enkefalinase og ACE
BRPI0312288B8 (pt) derivados de amidas
BR0308338A (pt) Derivados de nitrosodifenilamina e seu uso farmacêutico contra patologias de estresse oxidativo
DK0715623T3 (da) Blodpladeaggregationsinhibitorer
DK0630366T3 (da) Substituerede heterocycliske derivater, der er nyttige som blodpladeaggregeringsinhibitorer

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: ASTELLAS PHARMA INC. (JP)

Free format text: ALTERADO DE: YAMANOUCHI PHARMACEUTICAL CO., LTD.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A E 13A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2125 DE 27/09/2011.